Cargando…

High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study

BACKGROUND: Although both rheumatoid factor (RF) and anticyclic citrullinated peptide antibodies (anti-CCP) are useful for diagnosing rheumatoid arthritis (RA), the impact of these autoantibodies on the efficacy of tumor necrosis factor (TNF) inhibitors has been controversial. The aim of this post h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takeuchi, Tsutomu, Miyasaka, Nobuyuki, Inui, Takashi, Yano, Toshiro, Yoshinari, Toru, Abe, Tohru, Koike, Takao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581496/ https://www.ncbi.nlm.nih.gov/pubmed/28865493 http://dx.doi.org/10.1186/s13075-017-1401-2

Ejemplares similares

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study
por: Takeuchi, Tsutomu, et al.
Publicado: (2009)

Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2016)

Adjusting for sex and anti-CCP levels in linkage analysis of rheumatoid arthritis
por: Lebrec, Jérémie JP, et al.
Publicado: (2007)

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
por: Tanaka, Yoshiya, et al.
Publicado: (2011)

Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study
por: Hashimoto, Jun, et al.
Publicado: (2010)

Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2020)

Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial
por: Tanaka, Yoshiya, et al.
Publicado: (2016)

Collagen Autoantibodies and Their Relationship to CCP Antibodies and Rheumatoid Factor in the Progression of Early Rheumatoid Arthritis
por: Whittingham, Senga F., et al.
Publicado: (2017)

Thermal characteristics of rheumatoid feet in remission: Baseline data
por: Gatt, Alfred, et al.
Publicado: (2020)

The TNFA -857C/T Polymorphism: Association with Rheumatoid Arthritis and Anti-CCP Levels in a Mexican Population
por: Agraz-Cibrián, Juan Manuel, et al.
Publicado: (2019)

The association of anti-CCP antibodies with disease activity in rheumatoid arthritis
por: Serdaroğlu, Münevver, et al.
Publicado: (2008)

Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks
por: Takeuchi, Tsutomu, et al.
Publicado: (2013)

Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis
por: Okuyama, Ayumi, et al.
Publicado: (2010)

Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis
por: Oba, Koji, et al.
Publicado: (2017)

The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases
por: Chou, CT, et al.
Publicado: (2007)

Relation Between Anti-CCP Antibodies and Sharp Score in Rheumatoid Arthritis
por: Mekic, Mevludin, et al.
Publicado: (2020)

Low levels of anti-cyclic citrullinated peptide (CCP) 3.1 associated with diseases other than rheumatoid arthritis
por: Son, James J., et al.
Publicado: (2021)

The influence of the -94 Ins/Del ATTG polymorphism of NFkB on the anti-CCP antibody levels in patients with rheumatoid arthritis
por: Ayón-Pérez, Miriam Fabiola, et al.
Publicado: (2021)

Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study)
por: Izumi, Keisuke, et al.
Publicado: (2015)

Identification of potential autoantigens in anti-CCP-positive and anti-CCP-negative rheumatoid arthritis using citrulline-specific protein arrays
por: Poulsen, Thomas B. G., et al.
Publicado: (2021)

Baseline predictors of remission, pain and fatigue in rheumatoid arthritis: the TITRATE trial
por: Lee, Sook Yan, et al.
Publicado: (2021)

Correction: Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study)
por: Izumi, Keisuke, et al.
Publicado: (2016)

Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials
por: Aletaha, Daniel, et al.
Publicado: (2015)

Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study
por: Tanaka, Yoshiya, et al.
Publicado: (2014)

Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response
por: Valli, Atte, et al.
Publicado: (2022)

Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+
por: Harrold, Leslie R., et al.
Publicado: (2023)

Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2016)

Relationship Between Baseline and Early Changes in C‐Reactive Protein and Interleukin‐6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis
por: Wang, Jianmei, et al.
Publicado: (2016)

Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study
por: Nakamura, Seiji, et al.
Publicado: (2016)

Baseline Anti-blood Group Antibody Titers and their Response to Desensitization and Kidney Transplantation
por: Shah, B. V., et al.
Publicado: (2017)

Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients
por: Lee, Sang Jin, et al.
Publicado: (2015)

Anti-citrullinated protein antibodies in the diagnosis of rheumatoid arthritis (RA): diagnostic performance of automated anti-CCP-2 and anti-CCP-3 antibodies assays
por: Vos, Ine, et al.
Publicado: (2017)

Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs
por: Takeuchi, Tsutomu, et al.
Publicado: (2014)

Molecular remission at T cell level in patients with rheumatoid arthritis
por: Inamo, Jun, et al.
Publicado: (2021)

Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab
por: Fabris, Martina, et al.
Publicado: (2010)

Relationship between Anti-CCP Antibodies and Oxidant and Anti-Oxidant Activity in Patients with Rheumatoid Arthritis
por: Ediz, Levent, et al.
Publicado: (2011)

Correlation between high-frequency ultrasonography of patients with early rheumatoid arthritis and anti-CCP antibody
por: Yang, Jie, et al.
Publicado: (2019)

Erratum to “Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients”
por: Lee, Sang Jin, et al.
Publicado: (2017)

Rheumatoid factor and anti-CCP do not predict progressive joint damage in patients with early rheumatoid arthritis treated with prednisolone: a randomised study
por: Hafström, Ingiäld, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_i2cfkite4ammoe4q4h8fof3i0n